Plain-English translation of NCT06141369 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing mRNA-0523-L001, a personalized vaccine designed specifically for you based on your individual tumor's mutations. The vaccine works by training your immune system to recognize and attack cancer cells that have specific genetic changes. Researchers believe this approach could help people with advanced endocrine cancers—including adrenal, thyroid, thymic, and pancreatic tumors—when other treatments haven't worked or aren't available.
Advanced endocrine tumors are difficult to treat, and many patients run out of standard treatment options. Recent research shows that most of these tumors have unique mutations that could potentially be recognized by the immune system if it receives the right training—which is what this personalized vaccine aims to do.
You likely qualify if…
You likely don't qualify if…
After joining, researchers will collect a sample of your tumor tissue to identify its unique mutations and design your personalized vaccine. You will then receive the vaccine as injections over a period of time, with regular clinic visits to check your health and monitor how well the treatment is working. The study will track your tumor size, immune response, and how long your cancer remains controlled.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China